CN108245665A - Pharmaceutical composition and its preparation method and application - Google Patents
Pharmaceutical composition and its preparation method and application Download PDFInfo
- Publication number
- CN108245665A CN108245665A CN201810153586.3A CN201810153586A CN108245665A CN 108245665 A CN108245665 A CN 108245665A CN 201810153586 A CN201810153586 A CN 201810153586A CN 108245665 A CN108245665 A CN 108245665A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- drug
- preparation
- astragaloside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention provides a kind of pharmaceutical compositions and its preparation method and application, are related to pharmaceutical technology field, pharmaceutical composition provided by the invention, including Astragaloside IV, jamaicin, chlorogenic acid and insulin.Pharmaceutical composition provided by the invention, number of components are few, and formula is simple, by each component reasonable compatibility, it complements each other, hepatic injury can be effectively treated, the hepar damnification especially as caused by steatosis, and good effect, it is quick, economical and practical, uneasy to recur, clinical efficacy is better than conventional western medicine or Chinese patent drug.Also, its key component is natural extract, and long-time service has adverse reaction and toxic side effect, is worthy of popularization.The each component of formula ratio is uniformly mixed by the preparation method of aforementioned pharmaceutical compositions provided by the invention, is mixed with pharmaceutically acceptable auxiliary material; pharmaceutical preparation is prepared as, method is simple, simple operation; and active constituent in drug will not be destroyed, suitable for large-scale production.
Description
Technical field
The present invention relates to pharmaceutical technology field, more particularly, to a kind of pharmaceutical composition and its preparation method and application.
Background technology
Liver is the parenchymatous organ of intraperitoneal maximum, is a device in vertebrate body based on metabolic function
Official, and fully play deoxidation inside body, glycogen, the synthesis of secreted protein etc. is stored, undertakes the weight of human body
Want physiological function.Liver cell is poor to the tolerance of anoxic, therefore has arteria hepatica and portal vein to provide abundant blood supply, and have
Size bile duct is with blood vessel with row conveying bile.It is located at the deep of upper right abdomen, there is the protection of the lower wall of the chest and diaphram.
Liver is that obstacle occurs for any one of the hinge of fat metabolism, fat metabolic process link, can all cause liver
The steatosis of cell.The reason of causing hepatic steatosis is varied, such as：Lipoprotein dyssynthesis, neutral fat close
Into excessive, aliphatic acid oxidation or ester fat obstacle.In recent years, due to the influence of many factors such as living habit, dietary structure, fat
The incidence of fat denaturation has the tendency that gradually increasing, obesity, drug and drug poisoning, diabetes, gestation, hepatitis virus or strange
Special pathogenic infection etc. can all cause the generation of hepatic steatosis.But regardless of the origin cause of formation, hepatic steatosis has development
For liver fibrosis or even hepatic sclerosis, it is believed that fatty liver is the cercinoma prophase pathologic change of liver fibrosis and hepatic sclerosis.
The treatment of doctor trained in Western medicine at present is mainly cured then, but treatment time is long, less effective using lipid-loweringing, liver protection, drop enzyme to be main, long
Phase use has adverse reaction.Chinese medicine is treated based on dispersing stagnated hepatoqi, blood stasis dispersing and phlegm expelling, the liver fat of sale treatment currently on the market
The drug of denaturation is various, but the really good drug of therapeutic effect and few.
Therefore, a kind of formula of exploitation is simple, therapeutic effect is good and what is had no toxic side effect can treat hepatic steatosis
Drug it is particularly important.
In view of this, it is special to propose the present invention.
Invention content
First of the present invention is designed to provide a kind of pharmaceutical composition, numerous to alleviate drug in the prior art
The technical issues of more, treatment time length, less effective, long-time service have adverse reaction.
Second object of the present invention is to provide a kind of drug, comprising pharmaceutical composition provided by the invention, to alleviate
The technical issues of shortage can quickly and efficiently treat the drug of hepatic injury in the prior art.
Third object of the present invention is to provide the preparation method of said medicine, to alleviate system in the prior art
Preparation Method is complicated, it is cumbersome the technical issues of.
Fourth object of the present invention is to provide the production of above-mentioned pharmaceutical composition or drug preparing treatment hepatic injury
Application in product, with alleviate it is in the prior art not yet find can effectively, quick, formula simply and has no toxic side effect
The technical issues for the treatment of the product of hepatic injury.
The present invention provides a kind of pharmaceutical composition, described pharmaceutical composition includes：Astragaloside IV, jamaicin, chlorogenic acid
And insulin.
Further, described pharmaceutical composition includes：
7-18 parts of 1.5-2.6 parts of Astragaloside IV, 1-2.6 parts of jamaicin, 9-25 parts of chlorogenic acid and insulin.
Further, described pharmaceutical composition includes：
10-15 parts of 1.7-2.4 parts of Astragaloside IV, 1.2-2.4 parts of jamaicin, 12-22 parts of chlorogenic acid and insulin.
Further, described pharmaceutical composition includes：
11-14 parts of 1.9-2.2 parts of Astragaloside IV, 1.5-2.1 parts of jamaicin, 15-19 parts of chlorogenic acid and insulin.
The present invention also provides the drugs that above-mentioned pharmaceutical composition is prepared.
Further, the dosage form of the drug is solid pharmaceutical preparation；
Preferably, the solid pharmaceutical preparation is tablet, capsule, pill or granule.
Further, the drug further includes pharmaceutically acceptable auxiliary material；
Preferably, the pharmaceutically acceptable auxiliary material is included in wetting agent, adhesive, filler, disintegrant, lubricant
It is one or more.
The present invention also provides the preparation method of above-mentioned pharmaceutical composition, the preparation method includes：
The each component of formula ratio is uniformly mixed, is mixed with optionally pharmaceutically acceptable auxiliary material, is prepared as drug system
Agent.
In addition, the answering in the product for preparing treatment hepatic injury the present invention also provides above-mentioned pharmaceutical composition or drug
With.
Further, the hepatic injury is hepatic steatosis.
Pharmaceutical composition provided by the invention, including Astragaloside IV, jamaicin, chlorogenic acid and insulin.The present invention provides
Pharmaceutical composition, number of components are few, and formula is simple, by each component reasonable compatibility, complements each other, and can effectively treat liver damage
Wound, the hepar damnification especially as caused by steatosis, and good effect, quick, economical and practical, uneasy to recur, clinical efficacy
Better than conventional western medicine or Chinese patent drug.Also, its key component is natural extract, and long-time service has adverse reaction and poison pair
Effect, is worthy of popularization.
Drug provided by the invention, pharmaceutical composition provided by the present invention are prepared, and active constituent is simple, can
Quickly and efficiently treat hepatic injury.
The each component of formula ratio is uniformly mixed by the preparation method of said medicine provided by the invention, with can pharmaceutically connect
The auxiliary material mixing received, that is, be prepared as pharmaceutical preparation, method is simple, simple operation, and will not destroy active constituent in drug, is suitable for
Large-scale production.
Description of the drawings
It, below will be to specific in order to illustrate more clearly of the specific embodiment of the invention or technical solution of the prior art
Embodiment or attached drawing needed to be used in the description of the prior art are briefly described, it should be apparent that, in being described below
Attached drawing is some embodiments of the present invention, for those of ordinary skill in the art, before not making the creative labor
It puts, can also be obtained according to these attached drawings other attached drawings.
Fig. 1 is blank group rat liver HE coloration result figures provided by the invention；
Fig. 2 is model group rats liver HE coloration result figures provided by the invention；
Fig. 3 is 5 groups of rat liver HE coloration result figures of comparative example provided by the invention；
Fig. 4 is 6 groups of rat liver HE coloration result figures of comparative example provided by the invention；
Fig. 5 is 5 groups of rat liver HE coloration result figures of embodiment provided by the invention.
Specific embodiment
Technical scheme of the present invention is clearly and completely described below in conjunction with embodiment, it is clear that described reality
It is part of the embodiment of the present invention to apply example, instead of all the embodiments.Based on the embodiments of the present invention, the common skill in this field
Art personnel all other embodiments obtained without making creative work belong to the model that the present invention protects
It encloses.
The present invention provides a kind of pharmaceutical composition, including：Astragaloside IV, jamaicin, chlorogenic acid and insulin.
Main effective ingredient in astragalus polyose is polysaccharide and astragalin.Astragalin is divided into Astragalosid I, Astragaloside II, Huang
Stilbene glycosides IV.Wherein bioactivity most preferably astragalin IV, that is, Astragaloside IV.Astragaloside IV not only has the function of astragalus polyose,
Also some are the incomparable effects of astragalus polyose, and efficacy strength is conventional astragalus polyose more than 2 times, and antivirus action is even more
30 times of astragalus polyose.Since content is few, effect is good, even more there is the title of " super astragalus polyose ".Astragaloside IV can enhance machine
Body immunity, the disease resistance for improving body, have effects that antivirus action and resisting stress, while can also improve cardio-pulmonary function.
Jamaicin (Berberine) is a kind of alkaloid contained in coptis rhizome, is primarily present in Berberis and the coptis
In platymiscium.Has a broad antifungal spectrum has bacteriostasis to a variety of gram positive bacterias in vitro, wherein to hemolytic streptococcus, golden yellow
Staphylococcus, comma bacillus, shigella, Escherichia coli etc. have a stronger inhibiting effect, antibacterial, high concentration during low concentration
When sterilize.Infected by influenza, Amoeba, Leptospira, certain dermatophytes also have certain inhibiting effect.Dysentery bar
Bacterium, hemolytic streptococcus, staphylococcus aureus etc. easily generate drug resistance to this product.And can enhance leucocyte and liver it is netted in
The phagocytic activity of dermal system.It is mainly used for treating the alimentary infections such as gastroenteritis, the bacillary dysentery caused by sensitive pathogen.
Chlorogenic acid have extensive bioactivity, modern science the research of chlorogenic acid bioactivity has been deep into food,
The multiple fields such as health care, medicine and daily-use chemical industry.Chlorogenic acid is a kind of important bioactive substance, have antibacterial, it is antiviral,
Increase white blood cell, hepatic cholagogic, antitumor, lowering blood pressure and blood fat, remove the effects that free radical and stimulating central nervous system system.
Insulin (Regular insulin) can increase the utilization of glucose, can accelerate the anerobic glycolysis of glucose and have
Oxygen aoxidizes, and promotes the synthesis and storage of hepatic glycogen and muscle glycogen, and can promote convert glucose as fat, control decomposition of glycogen and
Gluconeogenesis, thus blood glucose can be reduced.In addition, this product can promote the synthesis of fat.Inhibit lipolysis, subtract ketoplasia
It is few, correct the various symptoms of ketosis acidaemia.It can promote the synthesis of protein, inhibit breaks down proteins.This product and glucose are same
Used time can promote potassium to enter in histocyte from extracellular fluid.
Above-mentioned each component is applied in combination pharmaceutical composition provided by the invention, and number of components are few, and formula is simple, by each
Component reasonable compatibility, complements each other, and can effectively treat hepatic injury, the hepar damnification especially as caused by steatosis, and treats
It imitates, quick, economical and practical, uneasy to recur, clinical efficacy is better than conventional western medicine or Chinese patent drug.Also, its key component is equal
For natural extract, long-time service has adverse reaction and toxic side effect, is worthy of popularization.
In one preferred embodiment, pharmaceutical composition is mainly made of by weight following component：
7-18 parts of 1.5-2.6 parts of Astragaloside IV, 1-2.6 parts of jamaicin, 9-25 parts of chlorogenic acid and insulin.
Wherein, Astragaloside IV for example can be, but be not limited to 1.5 parts, 1.6 parts, 1.7 parts, 1.8 parts, 1.9 parts, 2.0 parts,
2.1 parts, 2.2 parts, 2.3 parts, 2.4 parts, 2.5 parts or 2.6 parts；Jamaicin for example can be, but be not limited to 1 part, 1.2 parts, 1.5
Part, 1.8 parts, 2.0 parts, 2.1 parts, 2.4 parts or 2.6 parts；Chlorogenic acid for example can be, but be not limited to 9 parts, 12 parts, 15 parts, 17
Part, 19 parts, 22 parts or 25 parts；Insulin for example can be, but be not limited to 7 parts, 8 parts, 9 parts, 10 parts, 11 parts, 12 parts, 13 parts,
14 parts, 15 parts, 16 parts, 17 parts or 18 parts.
In one preferred embodiment, pharmaceutical composition is mainly made of by weight following component：
10-15 parts of 1.7-2.4 parts of Astragaloside IV, 1.2-2.4 parts of jamaicin, 12-22 parts of chlorogenic acid and insulin.
In a preferred embodiment, pharmaceutical composition is mainly made of by weight following component：
11-14 parts of 1.9-2.2 parts of Astragaloside IV, 1.5-2.1 parts of jamaicin, 15-19 parts of chlorogenic acid and insulin.
In a most preferred embodiment, pharmaceutical composition is mainly made of by weight following component：
12 parts of 2 parts of Astragaloside IV, 1.8 parts of jamaicin, 17 parts of chlorogenic acid and insulin.
When Astragaloside IV is 2 parts, jamaicin is 1.8 parts, green original by weight in pharmaceutical composition provided by the invention
When acid is 17 parts and insulin is 12 parts, compatible use is best to the therapeutic effect of hepatic injury, and each component obtains rationally should
With avoiding the waste of raw material.
The present invention also provides the drugs that above-mentioned pharmaceutical composition is prepared.
The active constituents of medicine is simple, can quickly and efficiently treat hepatic injury.
In one preferred embodiment, the dosage form of drug is solid pharmaceutical preparation.
Preferably, solid pharmaceutical preparation is tablet, capsule, pill or granule.
In one preferred embodiment, drug further includes pharmaceutically acceptable auxiliary material.
Preferably, the pharmaceutically acceptable auxiliary material is included in wetting agent, adhesive, filler, disintegrant, lubricant
It is one or more.
The present invention also provides the preparation method of above-mentioned drug, including：
The each component of formula ratio is uniformly mixed, is mixed with optionally pharmaceutically acceptable auxiliary material, is prepared as drug.
The preparation method of said medicine provided by the invention, method is simple, simple operation, and because its only apply it is simple
Hybrid manipulation, and be mixed in pharmaceutically acceptable auxiliary material, therefore, active constituent in drug will not be destroyed, suitable for scale
Production.
The present invention also provides the application of above-mentioned pharmaceutical composition or drug in the product for preparing treatment hepatic injury.
In one preferred embodiment, hepatic injury is hepatic steatosis.
In one preferred embodiment, the product for treating hepatic injury is drug.
In order to contribute to the clearer understanding present invention, below in conjunction with embodiment and comparative example to the technical side of the present invention
Case is described further.
Embodiment 1
A kind of pharmaceutical composition is present embodiments provided, is mainly made of by weight following component：
18 parts of 1.5 parts of Astragaloside IV, 2.6 parts of jamaicin, 9 parts of chlorogenic acid and insulin.
Embodiment 2
A kind of pharmaceutical composition is present embodiments provided, is mainly made of by weight following component：
7 parts of 2.6 parts of Astragaloside IV, 1 part of jamaicin, 25 parts of chlorogenic acid and insulin.
Embodiment 3
A kind of pharmaceutical composition is present embodiments provided, is mainly made of by weight following component：
15 parts of 1.7 parts of Astragaloside IV, 2.4 parts of jamaicin, 12 parts of chlorogenic acid and insulin.
Embodiment 4
A kind of pharmaceutical composition is present embodiments provided, is mainly made of by weight following component：
10 parts of 2.4 parts of Astragaloside IV, 1.2 parts of jamaicin, 22 parts of chlorogenic acid and insulin.
Embodiment 5
A kind of pharmaceutical composition is present embodiments provided, is mainly made of by weight following component：
12 parts of 2 parts of Astragaloside IV, 1.8 parts of jamaicin, 17 parts of chlorogenic acid and insulin.
Embodiment 6
A kind of pharmaceutical composition is present embodiments provided, is mainly made of by weight following component：
20 parts of 1.2 parts of Astragaloside IV, 3 parts of jamaicin, 7 parts of chlorogenic acid and insulin.
Embodiment 7
A kind of pharmaceutical composition is present embodiments provided, is mainly made of by weight following component：
5 parts of 3 parts of Astragaloside IV, 0.8 part of jamaicin, 28 parts of chlorogenic acid and insulin.
Embodiment 8
A kind of pharmaceutical composition is present embodiments provided, is mainly made of by weight following component：
12 parts of 20 parts of JINQI JIANGTANG PIAN (Longshunrong Pharmaceutical Factory, Tianjin Zhongxin Pharmaceutical Group Co., Ltd) and insulin.
Comparative example 1
This comparative example provides a kind of pharmaceutical composition, is mainly made of by weight following component：
12 parts of 1.8 parts of jamaicin, 17 parts of chlorogenic acid and insulin.
Comparative example 2
This comparative example provides a kind of pharmaceutical composition, is mainly made of by weight following component：
12 parts of 2 parts of Astragaloside IV, 17 parts of chlorogenic acid and insulin.
Comparative example 3
This comparative example provides a kind of pharmaceutical composition, is mainly made of by weight following component：
12 parts of 2 parts of Astragaloside IV, 1.8 parts of jamaicin and insulin.
Comparative example 4
This comparative example provides a kind of pharmaceutical composition, is mainly made of by weight following component：
17 parts of 2 parts of Astragaloside IV, 1.8 parts of jamaicin and chlorogenic acid.
Comparative example 5
JINQI JIANGTANG PIAN (Longshunrong Pharmaceutical Factory, Tianjin Zhongxin Pharmaceutical Group Co., Ltd).
Comparative example 6
Biosynthetic human insulin parenteral solution (Novo Nordisk Co., Ltd of Denmark；Specification：3mL/300 international units；
J20100117)。
In order to which the advantageous effect to pharmaceutical composition provided by the invention is further detailed, tested as follows：
The pharmaceutical composition that 1-7 of the embodiment of the present invention and comparative example 1-4 are provided takes the raw material of formula ratio to mix respectively
It is even, then mixed respectively with starch, tabletting, it is for use to be prepared as orally available drug.
1st, experimental animal and feed
Cleaning grade health male Wistar rat, weight 200g ± 10g, being purchased from Beijing dimension tonneau China biotechnology share has
Limit company, production licence：SCXK (capital) 2014-0008；All 20-25 DEG C of rat room temperatures, the daily alternating of illumination in 12 hours
(8am-8pm), free water are ingested.
High lipid food (HFD H10060：Fatty, protein, carbohydrate) it is purchased from Beijing China Fukang biotechnology stock
Part Co., Ltd.
2nd, experimental method
4 week old male and healthy Wistar rats 160, adaptability are fed after a week, are randomly divided into without any processing
Blank group (10) and high lipid food nursing group (150).High lipid food group rat feeds high lipid food after three weeks, by feeding high in fat
Material nursing group is randomly divided into 15 groups, every group 10.
In high lipid food nursing group, model group gavage gives distilled water (0.5mL/kg)；Remaining 14 groups are given reality respectively
Apply the drug that a 1-8 and comparative example 1-6 are provided, every group is given clinical equivalent dose medication regimen, wherein, embodiment 1-8 and
The dosage of comparative example 1-4 is 0.4g/kg, and the dosage of comparative example 5 is 0.5g/kg, and the dosage of comparative example 6 is 6.5IU/
kg.The daily set time is primary by 0.5ml/kg liquids/distilled water gastric infusion, successive administration 4 weeks.
After drug treatment four weeks, chloral hydrate anesthesia takes out rat liver, and 4% paraformaldehyde is fixed, and paraffin embedding is cut
Piece (3 μ m-thick) carries out HE dyeing, observes influence of each administration group to rat liver steatosis.The results are shown in table below：
| Group | Fat granule accounting (%) | Cell arrangement situation |
| Blank group | 0 | Neatly |
| Model group | 76.22 | It is disorderly |
| Embodiment 1 | 9.35 | Neatly |
| Embodiment 2 | 9.12 | Neatly |
| Embodiment 3 | 7.33 | Neatly |
| Embodiment 4 | 8.01 | Neatly |
| Embodiment 5 | 3.67 | Neatly |
| Embodiment 6 | 13.99 | It is relatively neat |
| Embodiment 7 | 15.92 | It is relatively neat |
| Embodiment 8 | 13.15 | It is relatively neat |
| Comparative example 1 | 68.21 | It is disorderly |
| Comparative example 2 | 61.25 | It is disorderly |
| Comparative example 3 | 69.33 | It is disorderly |
| Comparative example 4 | 53.34 | It is disorderly |
| Comparative example 5 | 55.37 | It is more disorderly |
| Comparative example 6 | 71.52 | It is disorderly |
By the test result of upper table it is found that model group rats hepatic steatosis situation is serious.Take the embodiment of the present invention
The rat for the drug that 1-8 is provided can effectively reduce fatty grain number amount in rat liver, ensure that cell arrangement is neat.And it takes
The feelings of hepatic steatosis caused by can not effectively alleviating feeding high lipid food with the rat of the comparative example 1-6 drugs provided
Condition.The drug that 1-8 of the embodiment of the present invention is provided is prompted to be complemented each other by each component reasonable compatibility, can be effectively reduced liver
Fat accumulation situation protects liver organization, achievees the purpose that treat hepatic injury.Delete wherein arbitrary component or using existing group
Point, it is undesirable to the therapeutic effect of hepatic steatosis.
Further, the weight fraction of each component for the pharmaceutical composition that embodiment 1-5 is provided is in the preferred of the present invention
In the range of.By the comparison of embodiment 1-5 and embodiment 6, embodiment 7 it is found that the medicine group of application preferred weight part of the present invention
It is more preferable to the therapeutic effect of hepatic steatosis to close object.By the comparison of embodiment 1-5 and embodiment 8 it is found that since golden stilbene drops
The effective active composition of sugar-tablet includes Astragaloside IV, jamaicin and chlorogenic acid, and therefore, the drug that Application Example 8 provides is to liver
Dirty fat accumulation also has certain therapeutic effect, but provide not as good as embodiment 1-5 pharmaceutical composition the effect of it is good.
Wherein, blank group HE coloration results as shown in Figure 1, the HE coloration results of model group as shown in Fig. 2, embodiment 5
Coloration result as shown in figure 5, the coloration result of comparative example 5 and comparative example 6 respectively as shown in Figure 3 and Figure 4.HE coloration results are shown
Show, blank group rat hepatocytes marshalling, size is uniform, and structural integrity, cytoplasm enriches；Model group liver cell is disorganized,
Caryoplasm cracks more, and loose, existing significant quantities of fat grain is connected between peripheral cell；5 groups of liver cell structures of comparative example are more complete, fat
Grain is slightly reduced；Compared to model group, 6 groups of liver cells of comparative example do not have significant change, and fat granule is more, and cell arrangement is disorderly；Implement
5 groups of liver cell fat granules of example significantly reduce, and how complete eucaryotic cell structure is.The prompting present invention most preferably scheme becomes rat liver fat
Property have apparent therapeutic effect.
Finally it should be noted that：The above embodiments are only used to illustrate the technical solution of the present invention., rather than its limitations；To the greatest extent
Pipe is described in detail the present invention with reference to foregoing embodiments, it will be understood by those of ordinary skill in the art that：Its according to
Can so modify to the technical solution recorded in foregoing embodiments either to which part or all technical features into
Row equivalent replacement；And these modifications or replacement, various embodiments of the present invention technology that it does not separate the essence of the corresponding technical solution
The range of scheme.
Claims (10)
1. a kind of pharmaceutical composition, which is characterized in that described pharmaceutical composition includes：Astragaloside IV, jamaicin, chlorogenic acid and pancreas
Island element.
2. pharmaceutical composition according to claim 1, which is characterized in that described pharmaceutical composition includes：
7-18 parts of 1.5-2.6 parts of Astragaloside IV, 1-2.6 parts of jamaicin, 9-25 parts of chlorogenic acid and insulin.
3. pharmaceutical composition according to claim 2, which is characterized in that described pharmaceutical composition includes：
10-15 parts of 1.7-2.4 parts of Astragaloside IV, 1.2-2.4 parts of jamaicin, 12-22 parts of chlorogenic acid and insulin.
4. pharmaceutical composition according to claim 3, which is characterized in that described pharmaceutical composition includes：
11-14 parts of 1.9-2.2 parts of Astragaloside IV, 1.5-2.1 parts of jamaicin, 15-19 parts of chlorogenic acid and insulin.
5. the drug that claim 1-4 any one of them pharmaceutical compositions are prepared.
6. drug according to claim 5, which is characterized in that the dosage form of the drug is solid pharmaceutical preparation；
Preferably, the solid pharmaceutical preparation is tablet, capsule, pill or granule.
7. drug according to claim 5 or 6, which is characterized in that the drug further includes pharmaceutically acceptable auxiliary material；
Preferably, the pharmaceutically acceptable auxiliary material includes one in wetting agent, adhesive, filler, disintegrant, lubricant
Kind is a variety of.
8. such as the preparation method of claim 5-7 any one of them drugs, which is characterized in that the preparation method includes：
The each component of formula ratio is uniformly mixed, is mixed with optionally pharmaceutically acceptable auxiliary material, is prepared as drug.
9. as prepared by claim 1-4 any one of them pharmaceutical composition or claim 5-7 any one of them drug
Treat the application in the product of hepatic injury.
10. application according to claim 9, which is characterized in that the hepatic injury is hepatic steatosis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810153586.3A CN108245665A (en) | 2018-02-22 | 2018-02-22 | Pharmaceutical composition and its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810153586.3A CN108245665A (en) | 2018-02-22 | 2018-02-22 | Pharmaceutical composition and its preparation method and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108245665A true CN108245665A (en) | 2018-07-06 |
Family
ID=62745129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810153586.3A Pending CN108245665A (en) | 2018-02-22 | 2018-02-22 | Pharmaceutical composition and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108245665A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110585262A (en) * | 2019-09-24 | 2019-12-20 | 上海中医药大学 | Traditional Chinese medicine composition for treating and/or preventing liver and gall diseases and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1965929A (en) * | 2006-11-01 | 2007-05-23 | 天津中新药业集团股份有限公司隆顺榕制药厂 | Preparation method of medicament for treating diabetes |
| CN101695520A (en) * | 2008-12-30 | 2010-04-21 | 天津医科大学 | Preparation method of medicament for treating diabetes |
| CN102357131A (en) * | 2011-10-12 | 2012-02-22 | 吉林敖东延边药业股份有限公司 | Method for preparing astragalus polysaccharide glucose-lowering capsule |
| CN103599211A (en) * | 2013-10-31 | 2014-02-26 | 济南星懿医药技术有限公司 | Pharmaceutical composition used for treating diabetes, and preparation method thereof |
-
2018
- 2018-02-22 CN CN201810153586.3A patent/CN108245665A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1965929A (en) * | 2006-11-01 | 2007-05-23 | 天津中新药业集团股份有限公司隆顺榕制药厂 | Preparation method of medicament for treating diabetes |
| CN101695520A (en) * | 2008-12-30 | 2010-04-21 | 天津医科大学 | Preparation method of medicament for treating diabetes |
| CN102357131A (en) * | 2011-10-12 | 2012-02-22 | 吉林敖东延边药业股份有限公司 | Method for preparing astragalus polysaccharide glucose-lowering capsule |
| CN103599211A (en) * | 2013-10-31 | 2014-02-26 | 济南星懿医药技术有限公司 | Pharmaceutical composition used for treating diabetes, and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| 翁建平: "《糖尿病看名医》", 30 July 2016, 中山大学出版社 * |
| 肖国士等: "《代谢与内分泌疾病验方集锦》", 31 August 2014, 人民军医出版社 * |
| 郭瑞臣等: "《药物使用手册》", 30 July 2015 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110585262A (en) * | 2019-09-24 | 2019-12-20 | 上海中医药大学 | Traditional Chinese medicine composition for treating and/or preventing liver and gall diseases and application thereof |
| CN110585262B (en) * | 2019-09-24 | 2021-12-03 | 上海中医药大学 | Traditional Chinese medicine composition for treating and/or preventing liver and gall diseases and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102273621B (en) | A kind of food of prevention and therapy diabetes or health food | |
| CN107648326B (en) | Preparation method of amaranth yellow dysentery-stopping oral liquid for livestock | |
| CN105343184A (en) | Composition and application thereof | |
| CN102068494A (en) | Health-care capsules with treatment effect on chemical liver injury and preparation method thereof | |
| CN1425447A (en) | Traditional Chinese medicine composition for curing child's dyspepsia and cough and its preparing method | |
| CN108245665A (en) | Pharmaceutical composition and its preparation method and application | |
| CN106389408A (en) | Application of polyoxymethylflavone, polyoxymethylflavone composition and polyoxymethylflavone preparation for prevention or treatment of hyperlipidemia | |
| CN103800352B (en) | Compound traditional Chinese medicinal effective component preparation for resisting alcoholic fatty liver disease and application thereof | |
| CN102240345A (en) | Compound Chinese herbal medicine preparation for preventing and treating Newcastle disease | |
| KR20230145464A (en) | Drug composition for treating hyperlipidemia and method for producing the same | |
| CN101085037A (en) | Traditional Chinese medicine preparation for animals and preparation method thereof | |
| CN103191175A (en) | Diarrhoea-stopping traditional Chinese medicine composition, capsule and application thereof | |
| CN113082106A (en) | Compound composition, application of compound composition in preparation of medicine for treating diabetic complications and medicine for treating diabetic complications | |
| CN103893300B (en) | A kind of Chinese medicine composition treating cow endometritis and preparation method and application | |
| CN108210745A (en) | One kind has immunoregulatory auxiliary hyperglycemic compound capsules and preparation method thereof | |
| CN110368429A (en) | Prevent and treat the Chinese medicine composition and preparation method thereof that bacillary enterogastritis draws dysentery | |
| CN107693598A (en) | A kind of compound preparation of reducing blood lipid and preparation method thereof | |
| CN103877126B (en) | Knurl lid intends the pharmaceutical usage of shelf fungus and the pharmaceutical composition for the treatment of tumour | |
| CN100360140C (en) | Calf-blood deprotein capsules and preparation thereof | |
| CN109394881A (en) | Prevent and treat pure Chinese medicine composition of poultry enterotoxin syndrome and preparation method thereof and application method | |
| CN104187658B (en) | Columba livia health care oral liquid and application thereof | |
| CN103272068B (en) | Chinese and western medicine compound preparation containing tilmicosin and preparation method thereof | |
| CN103142751A (en) | Traditional Chinese medicine composition for treating piglet iron-deficiency anemia | |
| CN109045128A (en) | A kind of extraction and preparation technique being sustained tablets of reducing blood fat | |
| CN108187051A (en) | Alpha-L-fucosidase and inhibitor are used to prepare the purposes of the drug of prevention treating myocardial ischemia damage |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |